Human alveolar barrier damage in COVID 19 associated lung failure
- Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
- Total publications:1 publications
Grant number: 01KI2082
Grant search
Key facts
Disease
COVID-19Start & end year
20202021Known Financial Commitments (USD)
$54,137.02Funder
Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)Principal Investigator
PendingResearch Location
GermanyLead Research Institution
Charité - Universitätsmedizin BerlinResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Disease pathogenesis
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Abstract: The aim of the project is to investigate whether the body's own substances are responsible for the damage to the lung tissue in COVID-19 patients who suffer from the so-called "Acute Respiratory Distress Syndrome" (ARDS). The investigation is to be carried out in the laboratory on lung cells. In addition, the aim is to investigate whether the suspected mechanism of action that triggers ARDS can be inhibited by an active ingredient that has already been tested in clinical studies for other indications. In the short to medium term, such studies could provide important insights for the treatment of severe cases of COVID-19. If the project is successful, a starting point for the development of a therapeutic agent could be identified in the medium to long term.; Research Type: discovery; Study population: not applicable
Publicationslinked via Europe PMC
Last Updated:a day ago
View all publications at Europe PMC